Laurus Labs has successfully completed the US Food and Drug Administration (USFDA) audit without observations - ZERO 483 for its Unit 2 (formulations unit). The inspection was carried out from February 26, 2018 to March 1, 2018.
Besides, the company has also received its maiden Approval from USFDA for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate Tablets 300mg is therapeutically equivalent to VIREAD Tablets 300mg of Gilead Science. Tenofovir Disoproxil Fumarate Tablets 300mg is used for treatment of HIV-1 infection in adults and paediatric patients 2 years of age and older.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
